ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3066-Epping-Northern-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
36
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07361510
Advanced
Phase 3
Recruiting
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%. (
CA266-0002
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6027 - Joondalup - Joondalup Health Campus
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07202091
Haem
Phase 2 / Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Stop-Ig) (
TRU-RPT-22-Stop-Ig
)
Doxycycline
tetracycline antibiotic
Leukaemia
Lymphoma
Multiple myeloma
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07202078
Haem
Phase 2 / Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Start Ig) (
TRU-RPT-22-Start-Ig
)
Doxycycline
tetracycline antibiotic
Leukaemia
Lymphoma
Multiple myeloma
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07202065
Haem
Phase 2 / Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy (Dose-Ig) (
TRU-RPT-22-Dose-Ig
)
Leukaemia
Lymphoma
Multiple myeloma
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07202052
Haem
Phase 2 / Phase 3
Recruiting
A Randomised Platform Trial Evaluating the Role of Interventions to Prevent Infection in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies - RATIONAL-PT (Core) (
TRU-RPT-22
)
Doxycycline
tetracycline antibiotic
Leukaemia
Multiple myeloma
Non-Hodgkin's lymphoma
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07007312
Haem
Phase 3
Recruiting
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (
KO-MEN-017
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06932562
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients (
EMN39
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06914128
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
PRMT5 inhibitor
NOT Glioblastoma
NOT High-grade glioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
NCT06875310
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (
CA239-0004
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3066 - Epping - Northern Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6027 - Joondalup - Joondalup Health Campus
NCT06717347
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) (
2140-010
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4812 - Townsville - Townsville University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06641414
Haem
Phase 3
Recruiting
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4). (
APG2575MG301
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Icon Cancer Centre Richmond
WA
6000 - Perth - Royal Perth Hospital
6168 - Cooloongup - Rockingham Hospital
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06170788
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (
TroFuse-007
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3066 - Epping - Northern Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (COMPLETED)
NCT04895436
Haem
Phase 2
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia (
ReVenG
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12626001210369
Curative
Not Applicable
Not yet recruiting
Bronchoscopic tumour ablation for immune priming to enhance neoadjuvant chemotherapy and immunotherapy in patients with resectable non-small cell lung cancer (
IMPRINT
study): A single arm open label feasibility study.
Nivolumab
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Non-small cell lung cancer
VIC
3011 - Footscray - Footscray Hospital
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
ACTRN12626000704392
Haem
Phase 2
Not yet recruiting
A Bayesian Phase II study with toxicity monitoring of elranatamab monotherapy in newly diagnosed systemic light-chain (AL) amyloidosis (
ENLIGHT
)
bispecific T-cell engager,BCMA-targeting
AL amyloidosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000201471
Haem
Phase 1 / Phase 2
Recruiting
ALLG MDS05 (MYDAS-T)/D3 (MESSAGE): Myelodysplasia Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement (
MDS05-D3
)
Cedazuridine
DNA methyltransferase inhibitor
Decitabine
Sturlimogene Erparepvec
bispecific-EGFR/CDH17 antibody-drug conjugate
cancer therapy
cancer therapy,DNA methyltransferase-targeting
cancer therapy,cytidine deaminase-targeting
cytidine deaminase inhibitor
oncolytic herpes simplex virus
unknown drug class
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12624000963527
Advanced
Phase 2 / Phase 3
Recruiting
A randomised platform trial evaluating the role of interventions to prevent infection in patients with acquired hypogammaglobulinemia secondary to haematological malignancies -
RATIONAL-PT
(Stop-Ig Domain)
Doxycycline
tetracycline antibiotic
Haematological malignancy
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000065594
Haem
Not Applicable
Recruiting
ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP1/2 inhibitor
PARP1 inhibitor
PARP2 inhibitor
PARP inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000180718
Curative
Not Applicable
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621001361897
Haem
Phase 2
Not yet recruiting
A single arm, open-label study of efficacy and safety of the Exportin 1 inhibitor selinexor in relapsed/refractory CNS Lymphoma and in relapsed/refractory CNS Myeloma (
EXCLAIM
)
XPO1 inhibitor
Diffuse large B-cell lymphoma
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
ACTRN12621001198819
Radonc
Not Applicable
Recruiting
A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (
RESOLUTE
)
Radiotherapy
cancer therapy
Colorectal cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3677 - Wangaratta - Northeast Health Wangaratta
ACTRN12621001037897
Haem
Phase 2
Recruiting
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (
IBIS-Study
)
CELMoD agent
anti-CD38 monoclonal antibody
glucocorticoid
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12621000586819
Radonc
Phase 2
Recruiting
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (
TROG-20.01-CHEST-RT
)
anti-PD-L1 monoclonal antibody
radiotherapy
topoisomerase inhibitor
Cancer
Lung cancer
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (30)
Not yet recruiting (6)
Recruitment Country and State
VIC (36)
NSW (28)
SA (23)
WA (18)
QLD (17)
ACT (8)
TAS (5)
NZ (2)
Phase
Phase 1 / Phase 2 (5)
Phase 2 (10)
Phase 2 / Phase 3 (6)
Phase 3 (11)
Trial Type
Haem (20)
Advanced (9)
Curative (5)
Radonc (2)
Cancer Therapy Class
PD-1/PD-L1
19%
DNA methyltransferase
19%
Bcl2
17%
PD-1
14%
EGFR
8%
PD-L1
8%
CD38
8%
cereblon
8%
CD20
8%
XPO1
8%
KRAS
6%
VEGFA
6%
BCMA
6%
VEGF
3%
KMT2A
3%
menin-MLL1
3%
menin
3%
PRMT5
3%
ROR1
3%
ER
3%
oestrogen axis
3%
IDH1
3%
IDH1 R132
3%
Trop2
3%
CD79b
3%
cytidine deaminase
3%
CTLA4
3%
PARP
3%
PI3K
3%
PI3K delta
3%
PI3Kalpha
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
proteasome
3%
CD47
3%
Facility
3066 - Epping - Northern Hospital (36)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (20)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (15)
3168 - Clayton - Monash Medical Centre (12)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (12)
3004 - Melbourne, Southbank - Alfred Health (11)
3128 - Box Hill - Box Hill Hospital - Eastern Health (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
2605 - Garran - The Canberra Hospital (8)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (7)
2170 - Liverpool - Liverpool Hospital (7)
5042 - Bedford Park - Flinders Medical Centre (7)
4102 - Woolloongabba - Princess Alexandra Hospital (7)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (7)
4575 - Birtinya - Sunshine Coast University Hospital (6)
6150 - Murdoch - Fiona Stanley Hospital (6)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (6)
6000 - Perth - Royal Perth Hospital (6)
2139 - Concord - Concord Repatriation General Hospital (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (4)
5112 - Elizabeth Vale - Lyell McEwin Hospital (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (4)
7000 - Hobart - Royal Hobart Hospital (4)
3011 - Footscray - Footscray Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2109 - North Ryde - Macquarie University Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
6027 - Joondalup - Joondalup Health Campus (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
3630 - Shepparton - Goulburn Valley Health (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4350 - Toowoomba - Toowoomba Hospital (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3199 - Frankston - PASO Medical (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
4812 - Townsville - Townsville University Hospital (1)
3121 - Richmond - Icon Cancer Centre Richmond (1)
6168 - Cooloongup - Rockingham Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2217 - Kogarah - St George Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4215 - Southport - ICON Cancer Care (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5000 - Adelaide - Cancer Research SA (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2031 - Randwick - Prince of Wales Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3002 - East Melbourne - Epworth Freemasons (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
4032 - Chermside - The Prince Charles Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
NA
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
Cancer Type
Cancer
Haematological malignancy
Solid tumour
Plasma cell disorder
Leukaemia
Multiple myeloma
Thoracic cancer
Lymphoma
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Non-Hodgkin's lymphoma
Upper gastrointestinal cancer
Acute myeloid leukaemia
Myeloid leukaemia
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Pancreatic cancer
Pancreatobiliary cancer
Colorectal cancer
Lower gastrointestinal cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Colorectal adenocarcinoma
Breast cancer
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
AL amyloidosis
Amyloidosis
EGFR-mutant non-small cell lung cancer
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy